You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物漲逾5% 信迪利單抗注射液銷售首年達到10億元的收入
格隆匯 03-31 11:54
格隆匯3月31日丨信達生物-B(1801.HK)現報31.75港元,漲5.31%,暫成交7856萬港元,最新總市值426億港元。公司昨晚公佈,2019年度,來自客户合約的收入達10.47億元(人民幣,下同),同比增長109.53倍;毛利9.23億元,同比增長96.36倍。上述收入包括因達伯舒®(信迪利單抗注射液)於2019年3月成功上市帶來的銷售收入10.16億元,而2018年度的總收入則為950萬元。達伯舒®為集團的首個商業化產品,以及唯一獲列入中華人民共和國國家醫保藥品目錄(“NRDL”)的PD-1抑制劑。公告還稱,公司各項業務總體在2月底3月初已逐漸恢復正常。公司將繼續密切關注疫情狀況,按計劃推進商業化,註冊和臨牀項目開發。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account